


## Dot1L-IN-2

Cat. No.:	HY-111390
CAS No.:	1940206-71-2
Molecular Formula:	C <sub>27</sub> H <sub>24</sub> N <sub>8</sub> O
Molecular Weight:	476.53
Target:	Histone Methyltransferase
Pathway:	Epigenetics
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	Dot1L-IN-2 is a potent, selective and orally bioavailable inhibitor of Dot1L (a histone methyltransferase), with an IC <sub>50</sub> and K <sub>i</sub> of 0.4 nM and 0.08 nM, respectively.
<b>IC<sub>50</sub> &amp; Target</b>	IC <sub>50</sub> : 0.4 nM (Dot1L) <sup>[1]</sup> K <sub>i</sub> : 0.08 nM (Dot1L) <sup>[1]</sup>
<b>In Vitro</b>	Dot1L-IN-2 is a potent, selective Dot1L inhibitor, with an IC <sub>50</sub> and K <sub>i</sub> of 0.4 nM and 0.08 nM, respectively. Dot1L-IN-2 potently inhibits H3K79 dimethylation (IC <sub>50</sub> , 16 nM), and blocks the activity of the HoxA9 promoter (IC <sub>50</sub> , 340 nM) in cellular systems. Dot1L-IN-2 also dramatically suppresses proliferation of the human MLL-rearranged leukemia cell line MV4-11 carrying the oncogenic MLL-AF4 fusion (IC <sub>50</sub> , 128 nM) <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

[1]. Chen C, et al. Discovery of Novel Dot1L Inhibitors through a Structure-Based Fragmentation Approach. ACS Med Chem Lett. 2016 Jun 1;7(8):735-40.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA